Clinical trials: Bulky Tumors
Lymphoma, Non-Hodgkin
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy…
- Trial name
- NCT00490490
- Testing
- Bexxar (tositumomab), External beam radiotherapy (XRT), Potassium Iodide (KI)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
This phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma.
- Trial name
- NCT01132807
- Testing
- Bleomycin Sulfate, Doxorubicin Hydrochloride, Procarbazine Hydrochloride
- Where
- 95 sites in United States
- Volunteers
- 164 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumors
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
The study allowed continued safety follow-up of patients who were on single agent dovitinib or dovitinib in combination with fulvestrant treatment in a Novartis-sponsored study which had met its primary endpoint and were…
- Trial name
- NCT02116803
- Testing
- dovitinib, fulvestrant
- Where
- 9 sites in United States, Austria and 5 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Hodgkin Lymphoma
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart injury, and others.
- Trial name
- NCT02505269
- Testing
- Brentuximab Vedotin, Adriamycin, Dacarbazine
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Lymphoma
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in…
- Trial name
- NCT01390584
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-Small Cell Lung Cancer, NSCLC
Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer
The investigators aim to evaluate the safety of delivering a one-time single fraction of Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose, conventionally fractionated concurrent…
- Trial name
- NCT01797471
- Testing
- Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2…
- Conditions
- Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma
- Trial name
- NCT02466971
- Testing
- Brachytherapy, Cisplatin, External Beam Radiation Therapy
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 450 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
Proton Therapy for Hodgkin Lymphoma
The purpose of this study is to reduce the risk of radiation related side effects and complications by treating with radiation (protons or photons) that exposes less of normal organs to low dose radiation.
- Trial name
- HL01 (NCT00850200)
- Testing
- Proton Radiation Plan, Conventional Photon Radiation Plan, Intensity Modulated Radiation Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Bladder Cancer
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy.
- Trial name
- CIRTiN-BC (NCT04779489)
- Testing
- personalized ultrafractionated stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Tumor
Evaluation of Patients With Bulky GIST Using Sunitinib
The primary purpose of this study is to determine if oral (mouth) delivery prior to tumor removal in patients with gastrointestinal stromal tumor (GIST) results in tumor shrinkage allowing for successful surgery.
- Trial name
- NCT01054911
- Testing
- Sunitinib, Surgery
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Uterine Cervical Cancer
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
The purpose of this study is first to establish what is the ideal dose of gemcitabine, a chemotherapy agent, when given in combination with radiation.
- Trial name
- NCT00184093
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Lymphoma
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with…
- Trial name
- NCT00496873
- Testing
- Cytoxan, Nipent, Rituxan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin Lymphoma, Adult
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
The standard chemotherapy for Hodgkin lymphoma is called ABVD which is a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine).
- Trial name
- NCT01578967
- Testing
- Brentuximab vedotin, ABVD
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Brentuximab is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a chemotherapy molecule.
- Trial name
- NCT01534078
- Testing
- Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Advanced Bulky Malignancies
Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy
Expand clinical literature on the use of Grid radiation with conventional external beam therapy. Vast majority of therapy is for palliative care to provide relief from pain, but has also shown a reduction in the size of tumor…
- Trial name
- NCT00765570
- Testing
- Spatially Fractioned Radiation Therapy, Treatment Group 1, Standard radiation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Summa Health System
Leukaemia
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL…
- Trial name
- NCT01313689
- Testing
- Ofatumumab, Physicians' Choice
- Where
- 80 sites in Austria, Belgium and 15 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
This research is being done in order to improve treatment outcomes in patients diagnosed with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated with use of radiation used in current…
- Trial name
- NCT01118026
- Testing
- ABVD, BEACOPP, radiation therapy
- Where
- 55 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology